Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368773 | 0.95 | NAAA (0.38) | LMNAHPGDNAAAFAAHALDH1A1 | |
| SCHEMBL369721 | 0.89 | LMNA (0.38) | LMNAHPGDNAAAFAAHALDH1A1 | |
| SCHEMBL10071004 | 0.87 | — | — | |
| SCHEMBL368547 | 0.87 | MAPK1 (0.39) | LMNAHPGDALDH1A1USP2TSHR | |
| SCHEMBL369231 | 0.87 | LMNA (0.38) | LMNAHPGDALDH1A1TSHRHSD17B10 | |
| SCHEMBL1222284 | 0.85 | LMNA (0.38) | LMNAHPGDALDH1A1USP2TSHR | |
| SCHEMBL367738 | 0.84 | NAAA (0.39) | LMNAHPGDNAAAFAAHALDH1A1 | |
| SCHEMBL15097362 | 0.84 | LMNA (0.37) | LMNAHPGDALDH1A1USP2TSHR | |
| SCHEMBL368792 | 0.83 | LMNA (0.38) | LMNAHPGDNAAAFAAHALDH1A1 | |
| SCHEMBL1221123 | 0.83 | MRGPRX4 (0.43) | LMNAHPGDNAAAFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| EP-2593460-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | Avexa Limited (AU) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012006680-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | AVEXA LIMITED (AU) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | EIF2AK2, IFNAR1, IRF3 | LMNA 4293/4885HPGD 2087/4885NAAA 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.